Gabriella Cotugno

Publications25
h-index11
Citations399
Highly Influential Citations6
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • A. Auricchio
  • 184 Publications, 7,633 Citations
  • J. Wilson
  • 752 Publications, 39,491 Citations
  • J. Hopwood
  • 465 Publications, 17,128 Citations
  • A. Maguire
  • 213 Publications, 13,504 Citations
  • Publications
  • Influence
AAV-mediated gene transfer for retinal diseases
Vectors based on the adeno-associated virus (rAAV) are able to transduce the retina of animal models, including non-human primates, for a long-term period, safely and at sustained levels. The ability… Expand
  • 44
  • 2
Long-term amelioration of feline Mucopolysaccharidosis VI after AAV-mediated liver gene transfer.
Mucopolysaccharidosis VI (MPS VI) is caused by deficient arylsulfatase B (ARSB) activity resulting in lysosomal storage of glycosaminoglycans (GAGs). MPS VI is characterized by dysostosis multiplex,… Expand
  • 51
  • 1
Gene therapy for mucopolysaccharidosis type VI is effective in cats without pre-existing immunity to AAV8.
Liver gene transfer with adeno-associated viral (AAV) 2/8 vectors is being considered for therapy of systemic diseases like mucopolysaccharidosis type VI (MPS VI), a lysosomal storage disease due to… Expand
  • 30
  • 1
Impact of Age at Administration, Lysosomal Storage, and Transgene Regulatory Elements on AAV2/8-Mediated Rat Liver Transduction
Liver-directed gene transfer is being investigated for the treatment of systemic or liver-specific diseases. Recombinant vectors based on adeno-associated virus serotype 8 (AAV2/8) efficiently… Expand
  • 14
  • 1
  • PDF
Similar therapeutic efficacy between a single administration of gene therapy and multiple administrations of recombinant enzyme in a mouse model of lysosomal storage disease.
Enzyme replacement therapy (ERT) has become the standard of care for several lysosomal storage disorders (LSDs). Despite ERT's undisputed efficacy, the requirement for multiple and costly… Expand
  • 17
  • 1
  • PDF
Biochemical, pathological, and skeletal improvement of mucopolysaccharidosis VI after gene transfer to liver but not to muscle.
Mucopolysaccharidosis VI (MPS VI) is caused by deficient activity of arylsulfatase B (ARSB), resulting in intralysosomal storage of dermatan sulfate (DS) and multisystem disease without central… Expand
  • 61
Inhibition of ocular neovascularization by hedgehog blockade.
Ocular neovascularization associated with proliferative diabetic retinopathy and age-related macular degeneration is the leading cause of severe visual loss in adults in developed countries.… Expand
  • 47
Robust RNAi enhancement via human Argonaute-2 overexpression from plasmids, viral vectors and cell lines
As the only mammalian Argonaute protein capable of directly cleaving mRNAs in a small RNA-guided manner, Argonaute-2 (Ago2) is a keyplayer in RNA interference (RNAi) silencing via small interfering… Expand
  • 49
Amelioration of both functional and morphological abnormalities in the retina of a mouse model of ocular albinism following AAV-mediated gene transfer.
X-linked recessive ocular albinism type I (OA1) is due to mutations in the OA1 gene (approved gene symbol GPR143), which is expressed in the retinal pigment epithelium (RPE). The Oa1 (Gpr143)… Expand
  • 36
  • PDF
Different serum enzyme levels are required to rescue the various systemic features of the mucopolysaccharidoses.
Mucopolysaccharidoses (MPSs) are lysosomal storage disorders characterized by progressive accumulation of glycosaminoglycans (GAGs) in various tissues. Enzyme replacement therapy (ERT) for several… Expand
  • 19